ARAY Stock Overview
Designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Accuray Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.76 |
| 52 Week High | US$3.05 |
| 52 Week Low | US$1.40 |
| Beta | 1.4 |
| 11 Month Change | -12.44% |
| 3 Month Change | -10.66% |
| 1 Year Change | -38.68% |
| 33 Year Change | -55.22% |
| 5 Year Change | -33.33% |
| Change since IPO | -93.82% |
Recent News & Updates
Recent updates
Accuray Remains A Perpetual 'Next Year Is Our Year' Story
Aug 18Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues
Aug 13
Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop
May 21Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results
May 04Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?
May 03Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp
Apr 07Is Accuray (NASDAQ:ARAY) A Risky Investment?
Feb 03Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge
Aug 17These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively
Apr 13The Return Trends At Accuray (NASDAQ:ARAY) Look Promising
Mar 14Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt
Dec 01Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price
Oct 27Accuray launches CyberKnife platform in Africa for cancer patients
Sep 30Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M
Aug 10Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden
Jul 08Accuray (NASDAQ:ARAY) Might Have The Makings Of A Multi-Bagger
Jun 15Accuray: Nothing Special
May 31Accuray Once Again Hits The Reset Button On Its Progress
Feb 09A Look At The Fair Value Of Accuray Incorporated (NASDAQ:ARAY)
Jan 28Shareholder Returns
| ARAY | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.6% | -0.7% | 0.6% |
| 1Y | -38.7% | 19.4% | 30.3% |
Return vs Industry: ARAY underperformed the US Medical Equipment industry which returned 19.4% over the past year.
Return vs Market: ARAY underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| ARAY volatility | |
|---|---|
| ARAY Average Weekly Movement | 18.5% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ARAY's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ARAY's weekly volatility has increased from 12% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 987 | Sandeep Chalke | www.accuray.com |
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems.
Accuray Incorporated Fundamentals Summary
| ARAY fundamental statistics | |
|---|---|
| Market cap | US$184.50m |
| Earnings (TTM) | -US$15.54m |
| Revenue (TTM) | US$446.55m |
0.4x
P/S Ratio-11.4x
P/E RatioIs ARAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARAY income statement (TTM) | |
|---|---|
| Revenue | US$446.55m |
| Cost of Revenue | US$303.43m |
| Gross Profit | US$143.12m |
| Other Expenses | US$158.67m |
| Earnings | -US$15.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 32.05% |
| Net Profit Margin | -3.48% |
| Debt/Equity Ratio | 381.9% |
How did ARAY perform over the long term?
See historical performance and comparison